Background: Epidemiologic studies have reported inconsistent findings regarding the association between the use of antidepressants and type 2 diabetes mellitus (DM) risk. We performed a meta-analysis to systematically assess the association between antidepressants and type 2 DM risk.
INTRODUCTION
Antidepressants are now one of the most frequently prescribed medications in outpatient medicine. 1) They are used widely not only for treating depression but also for controlling fibromyalgia 2) and postmenopausal problems. 3) As use of antidepressants increases, so does interest in their potential side effects. It has been reported that tricyclic antidepressants can cause weight-gain 4) and cardio-toxic effects when taken in overdose. 5) Recently, it has been suggested that the use of tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) may increase the risk of Furthermore, recent reports suggest that antidepressants may be associated with an increased risk of diabetes mellitus (DM). 7) There is controversy regarding the relationship between the use of antidepressants and the risk of DM. Some studies have found an increased risk of DM among antidepressant drug users, 8, 9) while others found no firm evidence. 10, 11) There is also disagreement regarding the reason for the association between the use of antidepressants and DM risk. Some studies propose that antidepressants may bio-pharmacologically affect glucose homeostasis and insulin sensitivity. 12, 13) On the other hand, it has been hypothesized that our understanding of the relationship between antidepressants and DM is confounded by depression, which has long been recognized to increase the incidence of DM. 14) Therefore, in the present study, we aimed to investigate the association between the use of antidepressants and the risk of DM via a meta-analysis of cohort studies, case-control studies and randomized clinical trials (RCT).
METHODS

Data Sources and Searches
Our review followed the Meta-analysis of Observational
Studies in Epidemiology guidelines and Preferred Reporting
Items for Systematic Reviews and Meta-Analyses statement. 15) We performed our search in MEDLINE (PubMed) (inception to Dec 31, 2011) , EMBASE (inception to Dec 31, 2011) , and the Cochrane Library (inception to Dec 31, 2011 ) by using selected common key words regarding antidepressants and diabetes mellitus in case-control studies, cohort studies, and RCTs.
In addition, we searched the bibliographies of relevant articles in order to identify additional studies of interest. 
Study Selection and Data Extraction
We searched case-control studies, cohort studies and RCTs reporting an association between antidepressive drugs and diabetes mellitus risk. Included studies had to contain both of the following: a risk estimate (odds ratio, relative risk, or hazard ratio) and its 95% confidence interval (CI). We only selected articles written in English and excluded those studies with no available data for outcome measures.
All studies retrieved from databases and bibliographies were independently reviewed by two authors, and disagreements were resolved by authors' consensus. Of the articles found in the three databases, duplicate articles and those that did not meet the selection criteria were excluded. We extracted the following data from the remaining studies: study name (first author), year of publication, country and design, study period, population characteristics, and type of antidepressants. Adjustment variables were also collected during data extraction. We obtained adjusted estimates with priority rather than those unadjusted.
Quality Assessment
We assessed the methodological quality of included studies using the Newcastle-Ottawa Scale (NOS) for quality of case control and cohort studies in meta-analyses. 16) The NOS is quite comprehensive and has been partially validated for assessing the quality of non-randomized studies in meta-analysis. The NOS is judged on three broad subscales: the selection of the study groups (4 items), the comparability of the groups (1 item), and the ascertainment of the exposure or outcome of interest for casecontrol or cohort studies, respectively (3 items). A 'star system' (range, 0 to 9) has been developed for assessment. In the current study, we considered a study awarded 8 or more stars as a highquality study, as standard criteria have not been established. [20] [21] [22] [23] [24] [25] [26] [27] 3 were reviews or correspondences, [28] [29] [30] and 3 were included totally or partially in another article. [31] [32] [33] As a result, we included 12 observational studies (3 case-control studies, 9 cohort studies, no RCTs), which ultimately met our inclusion criteria. Table 1 shows the main characteristics of the 12 reviewed studies. All studies were published in the 2000s. The countries in which the studies had been conducted were as follows: the United States (n = 6), 7, 8, 14, [33] [34] [35] Netherlands (n = 1), 11) the UK (n = 1), 36) Finland (n = 1), 9) Norway (n = 1), 10) Australia (n = 1), 37) and 
Statistical Analysis
Study Characteristics and Quality
Overall Risk of DM by Using Antidepressants
As seen in Table 2 , the use of antidepressants was significantly associated with an increased risk of DM in overall studies when using both a fixed-effect model (RR, 1.31; 95% CI, 1.26 to 1.37)
and random-effect model (RR, 1.49; 95% CI, 1.29 to 1.71). And the overall heterogeneity of the studies was high (I 2 = 85.8%). Figure 2 shows the association between the use of antidepressants and DM risk using a random-effect model.
Subgroup Meta-Analyses
As shown in Table 2 , SSRI use was associated with an increased risk of DM [8] [9] [10] 33, 35, 36) In a subgroup analysis of studies controlling specific risk factors, the associations between antidepressant use and risk of DM were consistent with the overall results. However, a pooled estimate of studies controlling physical activity 7,10,14,33,37) (RR, 1.18; 95% CI, 1.09 to 1.27) was attenuated comparing the overall result in the random effect model.
When we grouped studies by quality, both subgroups showed significantly increased risk of DM associated with the use of antidepressants. The pooled risk ratio of high quality studies 7-9,13,14,33-37) was particularly higher than overall results (RR, 1.67; 95% CI, 1.39 to 2.01).
Publication Bias
A publication bias was observed in the selected studies (Egger's test, P for bias = 0.09) (Figure 3 ).
DISCUSSION
Our meta-analysis suggests that the use of antidepressants is associated with an increased risk of DM. This finding is consistently observed in subgroup analyses by type of antidepressants (TCA, SSRI), study design, country and source of drug information. Generally, TCAs are known to increase the risk of cardiovascular disease as an adverse effect. 5) Relatively, SSRIs were thought to have fewer side effects, less toxicity and be more safe to use. 38) Thus, treatment with SSRIs has been increased to exceed the use of TCAs. 39, 40) Given the widespread use of anti-depressants, the implications of this increased risk are serious.
Several possible explanations exist for the association between the use of antidepressants and risk of DM. First, some anti-depressants may cause weight gain, and increased body weight may increase the risk of DM. Among antidepressants, TCA treatments are well known to be associated with weight gain 41, 42) through antihistaminergic effects. 41, 42) The association between SSRI treatment and weight change is complex. Some randomized controlled trials suggested that there were differences in weight increase caused by individual SSRIs. 43) Paroxetine users reported an increase in body weight. 43) From the results of subgroup analyses by individual antidepressants, we might explain these results as follows. Although there was no statistical significance, paroxetine showed a slightly higher risk ratio than citalopram, which was not reported to cause weight gain. 
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with adjustment for physical activity, the elevated risk of DM was lower than overall results. Unfortunately, other lifestyle factors such as diet or behavior were not considered in previous studies.
As a result, we assumed that physical activity level, at least, would have an influence on the risk of DM in antidepressant use.
The results, considering all of the above (body weight, depression severity, and physical activity), were still positive.
Moreover, the subgroup analyses were consistently positive regardless of study type, information source, country, and study quality. Consequently, it is not easy to deny the hypothesis that antidepressants themselves affect the risk of DM. This hypothesis is consistent with the result that the risk ratio in the subgroup with longer duration, one year or more, was higher than the subgroup with shorter duration, less than one year. This may reflect a mechanism in which antidepressants increase DM risk by their own neuroendocrine traits. It is assumed that antidepressants affect the hypothalamic-pituitary-adrenal axis, which results in an increase of plasma cortisol level and insulin resistance. Lastly, only one study in the young reported similar results.
Therefore, it is necessary to consider the risk of DM in young depressive patients and to perform further studies in the young of age.
Our meta-analysis has several limitations. First, all studies included in our meta-analysis were observational studies, and there seems to be publication bias surrounding this issue. To reduce publication bias, we performed a subsequent search for all relevant studies without any language restrictions, however, none of them met the inclusion criteria. Therefore, the uncertainty about these issues still remains until well-designed RCTs are 
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